Pixium Vision

74 articles about Pixium Vision

• Pixium Vision announces completion of implantations in the European pivotal trial PRIMAvera and confirms target read-out around the end of 2023 and regulatory submission in Europe in H1 2024

  12/15/2022

  Pixium Vision SA announces the completion of implantations in all the patients enrolled in the PRIMAvera European pivotal trial in atrophic dry age-related macular degeneration, also known as Geographic Atrophy.

• Pixium Vision announces participation in investor conferences in November and December 2022

  11/15/2022

  Pixium Vision SA, a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces that senior management will participate in the following investor conferences in November and December 2022:

• Pixium Vision announces the publication of peer-reviewed clinical data of the Prima System in Dry AMD in the Journal of Neural Engineering

  10/11/2022

  Pixium Vision SA announces the publication of a paper in the Journal of Neural Engineering outlining further data from its Prima System, a photovoltaic substitute of photoreceptors providing simultaneous use of the central prosthetic and peripheral natural vision, implanted in human patients with atrophic dry age-related macular degeneration to partially restore their vision.

• Pixium Vision announces participation in investor conferences and events in October 2022

  10/4/2022

  Pixium Vision SA announces that senior management will participate in the following investor events in October 2022:

• Pixium Vision to host open house event for investors on October 13th 2022 from 5 pm

  9/21/2022

  Pixium Vision SA, a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces it will host an open house event for investors on Thursday, October 13th, 2022.

• Pixium Vision announces implantation of first patient in Italy in Prima System European pivotal trial PRIMAvera

  9/13/2022

  Pixium Vision SA, a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces the successful first implantation of a patient in Italy in the PRIMAvera pivotal trial in atrophic dry age-related macular degeneration.

• Pixium Vision announces participation in upcoming investor conferences in September 2022

  9/6/2022

  Pixium Vision SA, a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces that senior management will participate in the following investor conferences during September 2022:

• Pixium Vision to attend H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on August 17, 2022

  8/11/2022

  Pixium Vision SA announces that Lloyd Diamond, Chief Executive Officer of Pixium Vision, will attend virtually the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference, taking place on Wednesday 17 August, 2022.

• Pixium Vision announces regulatory approval of remote rehabilitation system for patients in clinical trials

  8/3/2022

  Pixium Vision SA, a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces the approval of the remote rehabilitation system for patients enrolled in the PRIMAvera pivotal trial and the French Feasibility Study in atrophic dry age-related macular degeneration.

• Pixium Vision announces successful implantation of first patient in the Netherlands in Prima System European pivotal trial PRIMAvera

  7/26/2022

  Pixium Vision SA, a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces the successful implantation of the first patient in the Netherlands in the PRIMAvera pivotal trial in atrophic dry age-related macular degeneration.

• Pixium Vision announces its financial results for H1 2022 and provides a business update

  7/22/2022

  Paris, 22July2022 – 7.00 a.m. CET - Pixium Vision SA, a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independently, announces its financial results for the first half of 2022.

• Pixium Vision announces the implementation of a financing of a maximum nominal amount of €30 million, and the drawdown of a first tranche of €5.5 million.

  7/14/2022

  Pixium Vision announces that it has entered into a new Convertible Note financing agreement with US-based investor specializing in healthcare, European Select Growth Opportunities Fund on July 13, 2022, a maximum nominal amount of €30 million of notes redeemable in cash and/or new shares, without interest and without share warrants, over a maximum period of 36 months.

• Pixium Vision expands its Board of Directors with the appointment of Anja Krammer and August Moretti

  6/24/2022

  Pixium Vision SA, a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces the appointment of Anja Krammer and August Moretti as members of the company's Board of Directors.

• Pixium Vision announces the availability of its audited financial statements for the financial year 2021

  4/29/2022

  Pixium Vision SA announces that its audited financial statements for the year 2021 have been made available on the company’s website.

• Results of Combined General Meeting held on April 19, 2022

  4/28/2022

  The Combined Shareholders Meeting of Pixium Vision SA was held in Paris on on April 19, 2022 and adopted all the resolutions put to the vote relating to the granting to the Board of financial delegations, of delegations and authorisations allowing the allocation of equity warrants, free shares and stock options and relating to the maximum amount to be allocated to the directors as compensation for their activities.

• Pixium Vision announces its cash position at 31 March 2022 and provides an update on its activities and financial outlook until the end of 2022

  4/19/2022

  Pixium Vision SA announces a cash position of €10.4 million at 31 March 2022 and reports on its key developments.

• Pixium Vision announces FDA approval of clinical trial expansion of Prima System US feasibility study to Stanford Medicine

  3/29/2022

  Pixium Vision SA, a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces the approval by US FDA of the expansion of the Prima System* US feasibility study to include Stanford Medicine as a clinical site.

• Pixium Vision to participate in the 2022 Virtual Growth Conference presented by Maxim Group LLC and hosted by M-Vest on March 28 - 30

  3/24/2022

  Pixium Vision SA announces that Lloyd Diamond, Chief Executive Officer of Pixium Vision, has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest from March 28 to 30, 9.00 am to 5.00 pm EDT / 3.00 pm to 11.00 pm CET.

• Pixium Vision convenes a Combined General Meeting of Shareholders on April 19, 2022

  3/14/2022

  Pixium Vision SA announces that it will hold a combined general meeting of shareholders at 10:00 CET on April 19, 2022 at Pixium Vision’s headquarter office.

• Pixium Vision announces its unaudited financial results for 2021 and provides a business update

  2/22/2022

  Pixium Vision, a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independently, announces its financial results for 2021 and provides a business update.